Home > Publications database > Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. > print

001     142330
005     20240229105147.0
024 7 _ |a 10.1056/NEJMoa1805762
|2 doi
024 7 _ |a pmid:30403938
|2 pmid
024 7 _ |a 0028-4793
|2 ISSN
024 7 _ |a 1533-4406
|2 ISSN
024 7 _ |a altmetric:50960460
|2 altmetric
037 _ _ |a DKFZ-2019-00106
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Dimopoulos, Meletios A
|b 0
245 _ _ |a Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
260 _ _ |a Waltham, Mass.
|c 2018
|b MMS
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1549619555_21030
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor.Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone alone (control group). The primary end point was investigator-assessed progression-free survival.A total of 117 patients were randomly assigned to the elotuzumab group (60 patients) or the control group (57 patients). After a minimum follow-up period of 9.1 months, the median progression-free survival was 10.3 months in the elotuzumab group and 4.7 months in the control group. The hazard ratio for disease progression or death in the elotuzumab group as compared with the control group was 0.54 (95% confidence interval [CI], 0.34 to 0.86; P=0.008). The overall response rate was 53% in the elotuzumab group as compared with 26% in the control group (odds ratio, 3.25; 95% CI, 1.49 to 7.11). The most common grade 3 or 4 adverse events were neutropenia (13% in the elotuzumab group vs. 27% in the control group), anemia (10% vs. 20%), and hyperglycemia (8% vs. 7%). A total of 65% of the patients in each group had infections. Infusion reactions occurred in 3 patients (5%) in the elotuzumab group.Among patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor had failed, the risk of progression or death was significantly lower among those who received elotuzumab plus pomalidomide and dexamethasone than among those who received pomalidomide plus dexamethasone alone. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-3 ClinicalTrials.gov number, NCT02654132 .).
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Antibodies, Monoclonal, Humanized
|2 NLM Chemicals
650 _ 7 |a Immunologic Factors
|2 NLM Chemicals
650 _ 7 |a elotuzumab
|0 1351PE5UGS
|2 NLM Chemicals
650 _ 7 |a Thalidomide
|0 4Z8R6ORS6L
|2 NLM Chemicals
650 _ 7 |a Dexamethasone
|0 7S5I7G3JQL
|2 NLM Chemicals
650 _ 7 |a pomalidomide
|0 D2UX06XLB5
|2 NLM Chemicals
700 1 _ |a Dytfeld, Dominik
|b 1
700 1 _ |a Grosicki, Sebastian
|b 2
700 1 _ |a Moreau, Philippe
|b 3
700 1 _ |a Takezako, Naoki
|b 4
700 1 _ |a Hori, Mitsuo
|b 5
700 1 _ |a Leleu, Xavier
|b 6
700 1 _ |a LeBlanc, Richard
|b 7
700 1 _ |a Suzuki, Kenshi
|b 8
700 1 _ |a Raab, Marc-Steffen
|0 P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3
|b 9
|u dkfz
700 1 _ |a Richardson, Paul G
|b 10
700 1 _ |a Popa McKiver, Mihaela
|b 11
700 1 _ |a Jou, Ying-Ming
|b 12
700 1 _ |a Shelat, Suresh G
|b 13
700 1 _ |a Robbins, Michael
|b 14
700 1 _ |a Rafferty, Brian
|b 15
700 1 _ |a San-Miguel, Jesús
|b 16
773 _ _ |a 10.1056/NEJMoa1805762
|g Vol. 379, no. 19, p. 1811 - 1822
|0 PERI:(DE-600)1468837-2
|n 19
|p 1811 - 1822
|t The New England journal of medicine
|v 379
|y 2018
|x 1533-4406
909 C O |o oai:inrepo02.dkfz.de:142330
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEW ENGL J MED : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 50
|0 StatID:(DE-HGF)9950
|2 StatID
|b NEW ENGL J MED : 2017
920 1 _ |0 I:(DE-He78)G170-20160331
|k G170
|l Experimentelle Therapien hämatologischer Neoplasien
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G170-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21